Grammer L C, Ricketti A J, Schafer M F, Patterson R
Clin Orthop Relat Res. 1984 Sep(188):139-43.
Chymopapain has been approved for intradiscal injection in the United States and is expected to be used in approximately 100,000 patients per year. The need to identify the population at risk for anaphylaxis is obvious. Both in vivo and in vitro methods are available for measurement of IgE against chymopapain. This is a report of two cases of chymopapain allergy. One case discusses a 25-year-old woman who had rhinitis, asthma, and urticaria associated with occupational health hazards who was rejected for chemonucleolysis. The other case describes a 59-year-old man who had a predictably severe anaphylactic reaction to chymopapain and responded to treatment with epinephrine. Both patients had IgE antibody against chymopapain.
木瓜凝乳蛋白酶在美国已被批准用于椎间盘内注射，预计每年约有10万名患者使用。识别有过敏反应风险人群的必要性显而易见。体内和体外方法均可用于检测针对木瓜凝乳蛋白酶的IgE。本文报告了两例木瓜凝乳蛋白酶过敏病例。一例讨论了一名25岁患有鼻炎、哮喘和与职业健康危害相关荨麻疹的女性，她因化学溶核术被拒用该药物。另一例描述了一名59岁男性，他对木瓜凝乳蛋白酶出现了可预见的严重过敏反应，并对肾上腺素治疗有反应。两名患者均有针对木瓜凝乳蛋白酶的IgE抗体。
